Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer

Genes Chromosomes and Cancer

Volumn 50, Issue 8, 2011, Pages 662-671

  Barros Silva, João D ^a   Ribeiro, Franclim R ^a   Rodrigues, Ângelo ^a   Cruz, Ricardo ^a   Martins, Ana T ^a   Jerónimo, Carmen ^a,b   Henrique, Rui ^a,b   Teixeira, Manuel R ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYBRID PROTEIN; MYC PROTEIN; TMPRSS2 ERG FUSION PROTEIN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 8Q; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE REARRANGEMENT; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

AGED; BIOPSY; CHROMOSOMES, HUMAN, PAIR 8; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS;

EID: 79958025241     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20888     Document Type: Article

References (50)

1. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. 2000. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years. J Urol 164: 101-105.
2. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS. 2008. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27: 253-263.
3. Boormans JL, Hermans KG, Made AC, van Leenders GJ, Wildhagen MF, Collette L, Schroder FH, Trapman J, Verhagen PC. 2010. Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naive, node-positive prostate cancer. Eur Urol 57: 830-835.
4. Cerveira N, Ribeiro F, Peixoto A, Costa V, Henrique R, Jerónimo C, Teixeira M. 2006. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8: 826-832.
5. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera J-M, Pawitan Y, Lee C, Adami H-O, Mucci LA, Kantoff PW, Andersson S-O, Chinnaiyan AM, Johansson J-E, Rubin MA. 2007. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26: 4596-4599.
6. El Gammal AT, Brüchmann M, Zustin J, Isbarn H, Hellwinkel OJC, Köllermann J, Sauter G, Simon R, Wilczak W, Schwarz J, Bokemeyer C, Brümmendorf TH, Izbicki JR, Yekebas E, Fisch M, Huland H, Graefen M, Schlomm T. 2010. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res 16: 56-64.
7. Fitzgerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG. 2008. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: Results from a population-based study of prostate cancer. BMC Cancer 8: 230.
8. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. 2005. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. J Am Med Assoc 294: 433-439.
9. Furusato B, Gao C-L, Ravindranath L, Chen Y, Cullen J, Mcleod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA. 2008. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 21: 67-75.
10. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE, Gerald WL. 2009. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69: 1400-1406.
11. Gurel B, Iwata T, Koh C M, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM. 2008. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 21: 1156-1167.
12. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. 2001. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28: 555-565.
13. Hermans KG, Van Marion R, Van Dekken H, Jenster G, Van Weerden WM, Trapman J. 2006. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66: 10658-10663.
14. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. 2002. Cancer control with radical prostatectomy alone in 1, 000 consecutive patients. J Urol 167: 528-534.
15. Isariyawongse BK, Sun L, Banez LL, Robertson C, Polascik TJ, Maloney K, Donatucci C, Albala D, Mouraviev V, Madden JF, Moul JW. 2008. Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: The predictive role of age and prostate-specific antigen. Urology 72: 882-886.
16. Jalava SE, Porkka KP, Rauhala HE, Isotalo J, Tammela TL, Visakorpi T. 2009. TCEB1 promotes invasion of prostate cancer cells. Int J Cancer 124: 95-102.
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. 2009. Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
18. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL. 2009. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41: 524-526.
19. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin V. 2008. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105: 2105-2110.
20. Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, Van De Rijn M, Huntsman DG, Brooks JD, Pollack JR. 2007. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 20: 467-473.
21. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramäki OR, Visakorpi T. 2010. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 16: 2845-2851.
22. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB. 2007. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20: 538-544.
23. Miyoshi Y, Uemura H, Fujinami K, Mikata K, Harada M, Kitamura H, Koizumi Y, Kubota Y. 2000. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 43: 225-232.
24. Mosquera J-M, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG. 2009. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 15: 4706-4711.
25. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang L-Y, Stanimirovic A, Encioiu E, Neill M, Loblaw DA, Trachtenberg J, Narod SA, Seth A. 2007. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 97: 1690-1695.
26. Narod SA, Seth A, Nam R. 2008. Fusion in the ETS gene family and prostate cancer. Br J Cancer 99: 847-851.
27. Nupponen NN, Porkka K, Kakkola L, Tanner M, Persson K, Borg A, Isola J, Visakorpi T. 1999. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol 154: 1777-1783.
28. Paris PL, Albertson DG, Alers JC, Andaya A, Carroll P, Fridlyand J, Jain AN, Kamkar S, Kowbel D, Krijtenburg PJ, Pinkel D, Schroder FH, Vissers KJ, Watson VJ, Wildhagen MF, Collins C, Van Dekken H. 2003. High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol 162: 763-770.
29. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H. 2004. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13: 1303-1313.
30. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA. 2006. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66: 8337-8341.
31. Porter CR, Kodama K, Gibbons RP, Correa R, Jr., Chun FK, Perrotte P, Karakiewicz PI. 2006. 25-year prostate cancer control and survival outcomes: A 40-year radical prostatectomy single institution series. J Urol 176: 569-574.
32. Prensner JR, Chinnaiyan AM. 2009. Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev 19: 82-91.
33. 0 prostate cancer are potential markers for cancer progression. Mod Pathol 15: 35-44.
34. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS. 2010. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102: 678-684.
35. Ribeiro FR, Henrique R, Martins AT, Jerónimo C, Teixeira MR. 2007. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur Urol 52: 116-125.
36. Ribeiro FR, Jerónimo C, Henrique R, Fonseca D, Oliveira J, Lothe RA, Teixeira MR. 2006. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res 12: 3961-3970.
37. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. 2004. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3, 478 consecutive patients: Long-term results. J Urol 172: 910-914.
38. Rubio-Briones J, Fernandez-Serra A, Calatrava A, Garcia-Casado Z, Rubio L, Bonillo MA, Iborra I, Solsona E, Lopez-Guerrero JA. 2010. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol 183: 2054-2061.
39. Saramäki O, Willi N, Bratt O, Gasser TC, Koivisto P, Nupponen NN, Bubendorf L, Visakorpi T. 2001. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol 159: 2089-2094.
40. Saramäki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TLJ, Visakorpi T. 2008. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14: 3395-3400.
41. Sardana G, Dowell B, Diamandis EP. 2008. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 54: 1951-1960.
42. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. 2006. Confirmation of the high frequency of theTMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45: 717-719.
43. Teixeira MR. 2008. Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions. Am J Surg Pathol 32: 642-644.
44. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
45. Tsuchiya N, Slezak JM, Lieber MM, Bergstralh EJ, Jenkins RB. 2002. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer 34: 363-371.
46. van Dekken H, Paris PL, Albertson DG, Alers JC, Andaya A, Kowbel D, van der Kwast TH, Pinkel D, Schroder FH, Vissers KJ, Wildhagen MF, Collins C. 2004. Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis. Genes Chromosomes Cancer 39: 249-256.
47. Vieira J, Henrique R, Ribeiro FR, Barros-Silva JD, Peixoto A, Santos C, Pinheiro M, Costa VL, Soares MJ, Oliveira J, Jeronimo C, Teixeira MR. 2010. Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. Genes Chromosomes Cancer 49: 935-947.
48. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. 2003. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170: 1872-1876.
49. Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, Zielenska M, Squire JA. 2006. Three-Color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 8: 465-469.
50. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA. 2008. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 21: 1451-1460.